Drugs for Gastrointestinal Diseases Practice Questions

Q: Sulfasalazine is NOT used for the treatment of which of the following conditions?

Sarcoidosis. **Explanation:** Sulfasalazine is a prodrug consisting of **5-aminosalicylic acid (5-ASA)** linked to **sulfapyridine** by a covalent azo bond. Its therapeutic utility is primarily derived from its anti-inflammatory and immunomodulatory properties. **Why Sarcoidosis is the Correct Answer:** Sarcoidosis is a multisystem granulomatous disease [2]. The mainstay of treatment for symptomatic sarcoidosis is **Corticosteroids** (e.g., Prednisolone). In steroid-resistant cases, second-line agents include Methotrexate, Azathioprine, or TNF-alpha inhibitors (Infliximab). Sulfasalazine has no established role in the management of sarcoidosis. **Analysis of Other Options:** * **Ulcerative Colitis (UC):** Sulfasalazine is a classic first-line agent for inducing and maintaining remission in mild-to-moderate UC [1]. The azo bond is cleaved by colonic bacteria, releasing 5-ASA (Mesalamine) directly at the site of colonic inflammation [1]. * **Crohn’s Disease:** While less effective than in UC (due to the transmural nature of Crohn's), Sulfasalazine is used for colonic involvement in Crohn’s disease [1]. * **Rheumatoid Arthritis (RA):** Sulfasalazine is classified as a **DMARD** (Disease-Modifying Anti-Rheumatic Drug). In RA, the sulfapyridine moiety is thought to be the active component responsible for systemic immunomodulation. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits prostaglandin synthesis and leukotriene production. * **Side Effects:** Reversible **oligospermia** (common MCQ), megaloblastic anemia (due to folate deficiency—always supplement folic acid), and hypersensitivity reactions (Stevens-Johnson Syndrome). * **Metabolism:** Acetylation in the liver. "Slow acetylators" are at a higher risk of toxicity. * **Monitoring:** Baseline and periodic CBC and LFTs are required.

Q: Which of the following is a correct triple drug regimen for the treatment of Helicobacter pylori infection?

Omeprazole + Clarithromycin + Metronidazole. ***Omeprazole + Clarithromycin + Metronidazole*** - This is a **standard triple therapy regimen** containing **1 PPI (Omeprazole) + 2 antibiotics (Clarithromycin + Metronidazole)** - Also known as **PCM regimen**, recommended as first-line therapy for H. pylori eradication - Given for **14 days** with cure rates of 70-85% - Particularly useful in **penicillin-allergic patients** *Metronidazole + Omeprazole + Amoxicillin* - This is actually a **valid triple therapy** (PPI + Amoxicillin + Metronidazole = PAM regimen) - However, this combination is **less preferred** than clarithromycin-based regimens due to lower efficacy in areas with metronidazole resistance - Used as alternative when clarithromycin resistance is high *Omeprazole + Amoxicillin + Metronidazole* - Same as option A (PAM regimen), just reordered - Valid but **less preferred** than clarithromycin-based triple therapy *Metronidazole + Ciprofloxacin + Amoxicillin* - **Missing the PPI component** - incomplete triple therapy - Standard H. pylori triple therapy MUST include a **proton pump inhibitor** - Ciprofloxacin is not a first-line agent for H. pylori

Q: Which of the following drugs are used to treat chemotherapy-induced nausea and vomiting?

Granisetron + dexamethasone + aprepitant. ***Granisetron + dexamethasone + aprepitant***- This triple-therapy combination represents the gold standard for preventing and treating highly emetogenic chemotherapy (HEC)-induced nausea and vomiting (CINV).- **Granisetron** (a **5-HT3 receptor antagonist**) blocks acute CINV, **dexamethasone** (a corticosteroid) enhances the antiemetic effect, and **aprepitant** (an **NK-1 receptor antagonist**) covers the delayed phase of CINV.*Doxylamine + domperidone + aprepitant*- **Doxylamine** is primarily used for nausea in pregnancy (mixed with pyridoxine) and is not a standard first-line agent for CINV prophylaxis.- **Domperidone** (a D2 antagonist) is infrequently used for CINV due to concerns over QT prolongation and is significantly less effective than 5-HT3 antagonists.*Prochlorperazine + metoclopramide + domperidone*- This combination consists primarily of **dopamine D2 receptor antagonists** and is insufficient for prophylaxis against moderately or highly emetogenic chemotherapy.- It lacks both a **5-HT3 inhibitor** (crucial for acute CINV) and an **NK-1 inhibitor** (crucial for delayed CINV and highly emetogenic regimens).*Dexamethasone + metoclopramide + domperidone*- This regimen is missing the key highly potent antiemetics: the **5-HT3 receptor antagonist** (like granisetron or ondansetron) and the **NK-1 receptor antagonist** (like aprepitant), which are indispensable for highly emetogenic chemotherapy.- While **dexamethasone** is standard, relying solely on **metoclopramide** and **domperidone** (D2 antagonists) is an inadequate primary strategy against severe CINV.

Q: Which drug is most appropriate for treating diarrhea in a patient treated for colorectal carcinoma with 5-fluorouracil?

Loperamide. ***Loperamide*** - **Loperamide** is the standard, first-line agent used for controlling **chemotherapy-induced diarrhea (CID)**, especially that caused by 5-fluorouracil (5-FU). - High doses of loperamide are often required in a fixed, scheduled regimen (e.g., 2 mg every 2 hours) until diarrhea resolves, to decrease gut motility and intestinal fluid secretion. *Ciprofloxacin* - **Ciprofloxacin** is an antibiotic used when diarrhea is suspected to be infectious or for prophylaxis against **neutropenic fever**, but it is not the symptomatic treatment for 5-FU toxicity. - It does not address the underlying pathology of 5-FU induced enteritis, which involves mucosal damage and malabsorption. *Atropine* - **Atropine** is primarily used to treat acute **cholinergic syndrome** (early diarrhea, sweating, lacrimation) which is a major toxicity associated with the chemotherapy drug **Irinotecan**, not 5-FU. - As an anticholinergic, it is not the preferred or protocol-driven agent for managing severe, non-infectious 5-FU-induced diarrhea. *Ornidazole* - This is an **antibiotic/antiprotozoal** medication, mainly effective against organisms like *Giardia* or *Amoeba*. - It is not indicated for symptomatic management of non-infectious **chemotherapy-induced toxicity** resulting from the direct mucosal damage inflicted by 5-FU.

Q: A patient presents with GERD. Which drug helps in contraction of LES and increases gastric emptying?

Metoclopramide. ***Metoclopramide*** - It is a **prokinetic agent** that acts as a D2 dopamine receptor antagonist, which increases esophageal tone, enhances peristalsis, and facilitates **gastric emptying**. - It specifically increases the pressure of the **Lower Esophageal Sphincter (LES)**, reducing reflux associated with GERD. *Pantoprazole* - This is a **Proton Pump Inhibitor (PPI)** that reduces acid production by irreversible inhibition of the H+/K+-ATPase pump in parietal cells [1], [2]. - It does not have any significant effect on **LES contraction** or **gastric motility**. *Vonoprazan* - This is a **Potassium-Competitive Acid Blocker (P-CAB)**, which directly and reversibly inhibits the H+/K+-ATPase pump. - Like other acid suppressants, it decreases acid secretion but does not improve **LES function** or **gastric emptying**. *Ranitidine* - This is an **H2 receptor antagonist** that blocks histamine receptors on parietal cells, leading to decreased acid secretion [3]. - It treats GERD by reducing acidity but has no direct action on **LES tone** or stomach **motility**.

Q: Which one of the following agents used in the treatment of inflammatory Bowel Disease acts by inhibiting the enzyme 'Janus Kinase'?

Tofacitinib. ***Tofacitinib*** - **Tofacitinib** is an oral medication that functions as a small molecule **Janus Kinase (JAK) inhibitor**, primarily targeting JAK1 and JAK3. - By inhibiting JAK enzymes, tofacitinib disrupts the signaling pathways of several **cytokines** involved in inflammation, including those implicated in **inflammatory bowel disease (IBD)**. *Adalimumab* - **Adalimumab** is a monoclonal antibody that targets and neutralizes **tumor necrosis factor-alpha (TNF-α)**, a key inflammatory cytokine. - It is not a JAK inhibitor but rather works by blocking the interaction of TNF-α with its receptors on cell surfaces. *Vedolizumab* - **Vedolizumab** is an anti-integrin monoclonal antibody that selectively blocks the α4β7 integrin on lymphocytes. - This action prevents lymphocytes from migrating into the gastrointestinal tract, thereby reducing inflammation in IBD. *Infliximab* - **Infliximab** is a chimeric monoclonal antibody that, like adalimumab, targets and neutralizes **tumor necrosis factor-alpha (TNF-α)**. - It works by binding to soluble and transmembrane forms of TNF-α, preventing its pro-inflammatory effects.

Q: The total osmolarity of new oral rehydration solution formulation is:

245 mmol/litre. ***245 mmol/litre*** - The **New Oral Rehydration Solution (ORS)** formulation has a reduced osmolarity of **245 mOsm/L** compared to the original WHO ORS. - This reduced osmolarity aims to minimize stool output and vomiting, making it more effective for treating dehydration in children with acute diarrhea. *210 mmol/litre* - This osmolarity is lower than the recommended new ORS formulation and could potentially lead to a higher risk of **hyponatremia** if not carefully monitored. - While lower osmolarity solutions can reduce stool output, a substantially lower value might compromise adequate rehydration. *300 mmol/litre* - This value is characteristic of the **original WHO ORS** formulation, which had a higher osmolarity. - Higher osmolarity solutions, like the original ORS, can sometimes worsen diarrhea by drawing water into the lumen due to osmotic effects. *255 mmol/litre* - This osmolarity is slightly above the recommended **245 mOsm/L** for the new ORS formulation. - While possibly still effective, the optimal balance between efficacy and minimizing stool volume has been established with the 245 mOsm/L formulation.

Q: A 50-year-old male presented to the ER with history of road side accident. He was operated under spinal anesthesia. Post-op 1 day after the operation, the patient reported labored breathing, nausea and vomiting. Patient had last passed stool 3 days ago. On examination: Distended abdomen, Tympanic note, Scattered bowel sounds. Water soluble enema failed to relieve the symptoms. X ray abdomen and CT were ordered. Which of the following drugs have been approved to be given in the above condition?

Neostigmine. ***Neostigmine*** - This patient presents with symptoms and signs suggestive of **colonic pseudo-obstruction** (Ogilvie's syndrome), characterized by significant **abdominal distension**, nausea, vomiting, and tympanic note on examination after surgery. - **Neostigmine**, an **acetylcholinesterase inhibitor**, increases acetylcholine levels at the neuromuscular junction, promoting colonic motility and is a recognized FDA-approved treatment for acute colonic pseudo-obstruction (Ogilvie's syndrome). - Administered intravenously with continuous cardiac monitoring due to risk of bradycardia and bronchospasm. *Dantrolene* - **Dantrolene** is a direct-acting **skeletal muscle relaxant** used primarily in the treatment of **malignant hyperthermia** and spasticity. - It works by interfering with calcium release from the sarcoplasmic reticulum and has no direct role in treating colonic pseudo-obstruction. *Pralidoxime* - **Pralidoxime** is an **acetylcholinesterase reactivator** used as an antidote for **organophosphate poisoning**. - It helps to regenerate acetylcholinesterase, thereby reducing the cholinergic crisis, which is not the pathology seen in this patient. *Atropine* - **Atropine** is an **anticholinergic drug** that blocks the action of acetylcholine at muscarinic receptors, leading to decreased parasympathetic activity. - While it can be used to counteract bradycardia or reduce secretions, it would worsen intestinal motility in Ogilvie's syndrome, as it reduces rather than enhances cholinergic stimulation.

Q: Which drug is used in treatment of vertigo?

Cinnarizine. ***Cinnarizine***- **Cinnarizine** is an antihistamine and calcium channel blocker known for its anti-vertigo and anti-emetic properties [2].- It works by suppressing the **vestibular system** and reducing the excitability of sensory hair cells in the inner ear [1].*Metoclopramide*- **Metoclopramide** is a **dopamine receptor antagonist** primarily used as an anti-emetic and for treating gastroparesis.- While it can alleviate nausea and vomiting associated with vertigo, it does not directly treat the underlying sensation of **vertigo** itself by acting on the vestibular system.*Cisapride*- **Cisapride** is a **serotonin 5-HT4 receptor agonist** that acts as a gastroprokinetic agent, enhancing gastrointestinal motility [3].- It is not used for vertigo and has been associated with serious **cardiac arrhythmias**, leading to restricted use in many countries [3].*None of the options*- This option is incorrect because **Cinnarizine** is a well-established medication used in the treatment of vertigo [2].- Other options are not primarily indicated for vertigo treatment.

Q: Which of the following is not a prokinetic?

Loperamide derivative. **Loperamide derivative** - **Loperamide** is an **opioid receptor agonist** that acts on the mu-opioid receptors in the gut, primarily to **decrease gastrointestinal motility** and treat diarrhea. - Its mechanism of action directly opposes that of prokinetic agents, which aim to increase GI motility. *Macrolides* - Certain macrolide antibiotics, particularly **erythromycin**, act as **motilin receptor agonists** at low doses. - This agonism leads to increased gastric motility and can be used as a prokinetic in conditions like gastroparesis. *D2 blocker* - **Dopamine D2 receptor antagonists** (e.g., **metoclopramide**, **domperidone**) block the inhibitory effect of dopamine on cholinergic smooth muscle. - This blockade enhances acetylcholine release, leading to increased gastrointestinal motility and prokinetic effects. *5HT4 agonist* - **Serotonin 5-HT4 receptor agonists** (e.g., **cisapride**, **prucalopride**) stimulate the release of acetylcholine and other excitatory neurotransmitters in the enteric nervous system. - This action promotes increased gastrointestinal motility, making them effective prokinetic agents.

Question 1

Sulfasalazine is NOT used for the treatment of which of the following conditions?

Accepted Answer

Sarcoidosis

Answer

Crohn's disease

Answer

Rheumatoid arthritis

Answer

Ulcerative colitis

Question 2

Which of the following is a correct triple drug regimen for the treatment of Helicobacter pylori infection?

Accepted Answer

Omeprazole + Clarithromycin + Metronidazole

Answer

Metronidazole + Omeprazole + Amoxicillin

Answer

Omeprazole + Amoxicillin + Metronidazole

Answer

Metronidazole + Ciprofloxacin + Amoxicillin

Question 3

Which of the following drugs are used to treat chemotherapy-induced nausea and vomiting?

Accepted Answer

Granisetron + dexamethasone + aprepitant

Answer

Doxylamine + domperidone + aprepitant

Answer

Prochlorperazine + metoclopramide + domperidone

Answer

Dexamethasone + metoclopramide + domperidone

Question 4

Which drug is most appropriate for treating diarrhea in a patient treated for colorectal carcinoma with 5-fluorouracil?

Accepted Answer

Loperamide

Answer

Ciprofloxacin

Answer

Atropine

Answer

Ornidazole

Question 5

A patient presents with GERD. Which drug helps in contraction of LES and increases gastric emptying?

Accepted Answer

Metoclopramide

Answer

Vonoprazan

Answer

Ranitidine

Answer

Pantoprazole

Question 6

Which one of the following agents used in the treatment of inflammatory Bowel Disease acts by inhibiting the enzyme 'Janus Kinase'?

Accepted Answer

Tofacitinib

Answer

Adalimumab

Answer

Vedolizumab

Answer

Infliximab

Question 7

The total osmolarity of new oral rehydration solution formulation is:

Accepted Answer

245 mmol/litre

Answer

210 mmol/litre

Answer

300 mmol/litre

Answer

255 mmol/litre

Question 8

A 50-year-old male presented to the ER with history of road side accident. He was operated under spinal anesthesia. Post-op 1 day after the operation, the patient reported labored breathing, nausea and vomiting. Patient had last passed stool 3 days ago. On examination: Distended abdomen, Tympanic note, Scattered bowel sounds. Water soluble enema failed to relieve the symptoms. X ray abdomen and CT were ordered. Which of the following drugs have been approved to be given in the above condition?

Accepted Answer

Neostigmine

Answer

Dantrolene

Answer

Pralidoxime

Answer

Atropine

Question 9

Which drug is used in treatment of vertigo?

Accepted Answer

Cinnarizine

Answer

Metoclopramide

Answer

Cisapride

Answer

None of the options

Question 10

Which of the following is not a prokinetic?

Accepted Answer

Loperamide derivative

Answer

Macrolides

Answer

D2 blocker

Answer

5HT4 agonist

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?